Abstract: A method is provided for detecting a cancer in an individual, the method comprising detection of a deletion in the nucleic acid sequence between residues 10743 and 14125 in mitochondrial DNA by extracting the mitochondrial DNA (mtDNA) from the biological sample obtained from the individual and quantifying the amount of mtDNA in the sample having a deletion in the nucleic acid sequence between approximately residues 10743 and 14125 of the mtDNA genome, and comparing the amount of mtDNA in the sample having the deletion to at least one known reference sample. Kits for conducting the method are also provided.
Type:
Grant
Filed:
June 3, 2019
Date of Patent:
September 7, 2021
Assignee:
MDNA Life Sciences, Inc.
Inventors:
Ryan L. Parr, Robert Thayer, Gabriel D. Dakubo, Jennifer Creed, Kerry Robinson, Andrea Maggrah, Brian Reguly
Abstract: Mitochondrial DNA deletions useful for the detection of cancers and sun exposure are provided. In particular, methods and kits for detecting mitochondrial DNA deletions for the early detection, diagnosis and progression of prostate cancer, sun exposure and non-melonoma skin cancer are provided.
Type:
Grant
Filed:
August 29, 2017
Date of Patent:
February 2, 2021
Assignee:
MDNA Life Sciences Inc.
Inventors:
Ryan L. Parr, Robert Thayer, Gabriel Dakubo, Jennifer Creed, Kerry Robinson, Andrea Maggrah, Brian Reguly, Andrew Harbottle, Mark Birch-Machin
Abstract: Methods and kits for predicting, diagnosing and monitoring cancer, wherein the methods comprise quantifying mitochondrial DNA mutations in biological samples. The methods of the invention may also be effective in screening for new therapeutic agents and treatment regimens and may also be useful for monitoring the response of a subject to a preventative or therapeutic treatment.
Type:
Application
Filed:
September 1, 2019
Publication date:
December 19, 2019
Applicant:
MDNA Life Sciences, Inc.
Inventors:
Ryan Parr, Jennifer Creed, Kerry Robinson, Andrea Maggrah, Katrina Maki, Gabriel Dakubo, Brian Reguly, Andrew Harbottle, Jude Alexander
Abstract: The present invention relates to methods for predicting, diagnosing and monitoring cancer. The methods comprise obtaining biological samples, extracting mitochondrial DNA (mtDNA) from the samples, quantifying mitochondrial DNA mutation in the sample and comparing the level of mtDNA mutation with a reference value. The methods of the invention may also be effective in screening for new therapeutic agents and treatment regimes, and may also be useful for monitoring the response of a subject to a preventative or therapeutic treatment.
Type:
Grant
Filed:
April 6, 2018
Date of Patent:
September 3, 2019
Assignee:
MDNA Life Sciences, Inc.
Inventors:
Ryan Parr, Jennifer Creed, Kerry Robinson, Andrea Maggrah, Katrina Maki, Gabriel Dakubo, Brian Reguly, Andrew Harbottle, Jude Alexander
Abstract: A method for detecting cancer in an individual comprising detecting a deletion in the nucleic acid sequence between residues 10743 and 14125 in mitochondrial DNA, obtaining a biological sample from the individual, extracting the mitochondrial DNA (mtDNA) from the sample, quantifying the amount of mtDNA in the sample having a deletion in the nucleic acid sequence between residues 10743 and 14125 of the mtDNA genome, and comparing the amount of mtDNA in the sample having the deletion to at least one known reference sample.
Type:
Grant
Filed:
March 27, 2017
Date of Patent:
June 4, 2019
Assignee:
MDNA Life Sciences Inc.
Inventors:
Ryan L. Parr, Robert Thayer, Gabriel D. Dakubo, Jennifer Creed, Kerry Robinson, Andrea Maggrah, Brian Reguly
Abstract: The present invention provides novel mitochondrial fusion transcripts and the parent mutated mtDNA molecules that are useful for predicting, diagnosing and/or monitoring cancer. Hybridization probes complementary thereto for use in the methods of the invention are also provided.
Type:
Grant
Filed:
February 20, 2015
Date of Patent:
April 23, 2019
Assignee:
MDNA Life Sciences Inc.
Inventors:
Ryan Parr, Brian Reguly, Gabriel Dakubo, Jennifer Creed, Kerry Robinson
Abstract: The present invention relates to methods for predicting, diagnosing and monitoring cancer. The methods comprise obtaining biological samples, extracting mitochondrial DNA (mtDNA) from the samples, quantifying mitochondrial DNA mutation in the sample and comparing the level of mtDNA mutation with a reference value. The methods of the invention may also be effective in screening for new therapeutic agents and treatment regimes, and may also be useful for monitoring the response of a subject to a preventative or therapeutic treatment.
Type:
Application
Filed:
April 6, 2018
Publication date:
August 16, 2018
Applicant:
MDNA Life Sciences, Inc.
Inventors:
Ryan Parr, Jennifer Creed, Kerry Robinson, Andrea Maggrah, Katrina Maki, Gabriel Dakubo, Brian Reguly, Andrew Harbottle, Jude Alexander
Abstract: Mitochondrial DNA deletions useful for the detection of cancers and sun exposure are provided. In particular, methods and kits for detecting mitochondrial DNA deletions for the early detection, diagnosis and progression of prostate cancer, sun exposure and non-melonoma skin cancer are provided.
Type:
Grant
Filed:
August 27, 2014
Date of Patent:
August 29, 2017
Assignee:
MDNA Life Sciences Inc.
Inventors:
Ryan L. Parr, Robert Thayer, Gabriel Dakubo, Jennifer Creed, Kerry Robinson, Andrea Maggrah, Brian Reguly, Andrew Harbottle, Mark Birch-Machin